Navigation Links
Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
Date:8/7/2012

SAN FRANCISCO, Aug. 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today the start of a Phase 2 study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at Stanford Cancer Institute. The Phase 2 study is an investigator-sponsored trial being conducted under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigators Seema Nagpal, M.D. and Pamela Kunz, M.D.

"Patients with bevacizumab-resistant high-grade glioma currently have little to no treatment options to help them manage their disease," said Dr. Recht. "We know that the mechanism of topoisomerase I inhibition has resulted in anti-tumor activity in gliomas in the past.  As a result, we are interested in evaluating etirinotecan pegol, this new targeted topoisomerase I inhibitor, which provides sustained exposure of drug metabolite to tumor cells."

The primary endpoint of the Phase 2 study is the six-week progression free survival (PFS) rate. Secondary endpoints include survival from time of first etirinotecan pegol infusion, overall survival from date of pathologic diagnosis or confirmation of high-grade glioma, and the safety profile of etirinotecan pegol in patients with bevacizumab-resistant high-grade glioma. The open label, single-arm trial is expected to enroll approximately 20 patients who will receive etirinotecan pegol once every three weeks as monotherapy.

"Etirinotecan pegol has demonstrated promising results in drug-resistant solid tumors, such as advanced and heavily pre-treated breast and ovarian cancers," said Robert Medve, M.D., Senior Vice President and Chief Medical Officer of Nektar Therapeutics.  "Recognizing the high unmet need in glioma, we are very pleased to support Dr. Recht and his colleagues with this study of single-agent etirinotecan pegol in this se
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and LYON, France , ... LLY ) and Adocia (Euronext Paris: FR0011184241 ... on developing an ultra-rapid insulin, known as BioChaperone Lispro, ... 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® ... Lilly and Adocia will develop BioChaperone Lispro with ...
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... PARK, Calif., Jan. 11 ForteBio®, Inc., a leading ... biotherapeutic and pharmaceutical products, today announced the launch of ... Kit for use on the company,s Octet platform. The ... measure levels of Protein A with unprecedented speed and ...
... , , CHICAGO, Jan. 11 ... single-database, fully-integrated electronic health record (EHR), practice management ... within a series of more than a dozen ... events today through January 15 at the Integrating ...
Cached Medicine Technology:ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments 2ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments 3Greenway Medical Technologies Advances Interoperability at Integrating the Healthcare Enterprise (IHE) North America Connectathon 2Greenway Medical Technologies Advances Interoperability at Integrating the Healthcare Enterprise (IHE) North America Connectathon 3Greenway Medical Technologies Advances Interoperability at Integrating the Healthcare Enterprise (IHE) North America Connectathon 4Greenway Medical Technologies Advances Interoperability at Integrating the Healthcare Enterprise (IHE) North America Connectathon 5
(Date:12/19/2014)... Balfleet.com , a leading dress company of wedding ... All the old and new customers can get a ... well-known for its high quality trendy women’s dresses, like ... more. Its formal dresses are quality made and come ... an elegant look when paired with any accessory. ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Energy ... Bedsheets are now available. Celliant, the world’s leading ... sheets and pillowcases. , There are a number ... additional circulation, increased oxygenation and balanced body temperature; ... healing and pain relief; enhanced athletic performance; and ...
(Date:12/19/2014)... 2014 Eufaula, Oklahoma, located just 9 ... the state’s largest lake with more than 600 miles ... to a little more than 3,000 residents, hosted its ... the 6th of December. , Featuring Santa, Christmas lights ... Eufaula on Main Street. Narconon Arrowhead’s parade float ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 The print ... Home and Business subscription of the Toronto Star, with ... readership of 622,169. The digital component is distributed nationally ... network of top news sites and partner outlets. To ... here . , The publication features an exclusive ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Potentially illness-causing E. coli ... at farmers markets, according to a new study. ... vendors from 13 farmers markets in Los Angeles and ... Out of almost 150 samples tested, 24 percent were ... salmonella, according to the researchers. Both types of ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... minor injuries from a series of explosions at an oil ... reported to have been triggered accidentally, but the matter is ... Trust maintained that only two people were in need of ... irritating the eyes, making people cough, and feel nauseous. The ...
... Organization has arrived in northwestern Pakistan to inspect the damage ... ,Lee is here to check on preparations being made for ... ,His agency says its main immediate task is to immunize ... off epidemics. Some 400,000 children have already been immunized against ...
... of its institution, Lasik, the eye surgery that corrects vision ... man. // An average procedure costs somewhere between $3,000 to ... ,Moreover, there are still question marks over the efficacy of ... is estimated that over 18 percent of the people require ...
... a New Year's resolution to get rid of her nicotine ... habit will have on her growing kids. // ,The ... two-year-old Cary are approaching an impressionable age, when kids become ... have to stop as my kids are at an age ...
... and her team from Virginia have developed a POCKET ... the personal information of the children.// The POCKET (Parental ... information of children’s who are using the internet for ... the applications may ask for personal information and the ...
... of breast cancer is the new nine week course of ... ,Herceptin is a monoclonal antibody that attacks the HER-2 ... breast cancers. ,The results of the combination therapy ... alone. ,A study was conducted by Finland researchers ...
Cached Medicine News:Health News:LASIK Treatments Still To Reach Common Man 2
Trans-Blot Plus Gel/Cassette Assembly Tray...
PosiBlot 30-30 Masks...
A blotter fit for use with the incredible new Criterion precast gel system, the Criterion blotter combines excellent blotting efficiency with the flexibility of the Trans-Blot system and the ease-of-...
... using the Antigen-Antibody Pens-Using a proprietary and ... specialized fountain pens, called Antigen-Antibody pens-TM, that ... the blotting membranes in any form or ... colored dyes helps to see antigen being ...
Medicine Products: